NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
NANOBIOTIX

BRIEF

published on 11/17/2025 at 15:31, 17 days 13 hours ago

The Goldman Sachs Group reduces its stake in NANOBIOTIX

Actions Goldman Sachs NANOBIOTIX 5% Threshold Title Loan
BRIEF

published on 11/13/2025 at 22:20, 21 days 6 hours ago

Nanobiotix Advances Curadigm Nanoprimer Platform for Improved Drug Delivery

Nanotechnology Drug Delivery NANOBIOTIX Curadigm Platform Therapeutic Vaccines
PRESS RELEASE

published on 11/13/2025 at 22:15, 21 days 6 hours ago

NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Nanobiotix announces advancements in Curadigm Nanoprimer platform with new patent applications, pre-clinical data, and external collaborations, aiming to revolutionize drug delivery

Pre-clinical Data Patent Applications NANOBIOTIX Curadigm Nanoprimer External Collaborations
BRIEF

published on 11/11/2025 at 22:20, 23 days 6 hours ago

Nanobiotix will participate in the Jefferies London Healthcare conference

Biotechnology Oncology NANOBIOTIX Nanoparticles Jefferies Conference
PRESS RELEASE

published on 11/11/2025 at 22:15, 23 days 6 hours ago

NANOBIOTIX to Participate in Jefferies London Healthcare Conference
Nanobiotix to participate in Jefferies London Healthcare Conference on Nov 17, 2025, with company management as presenters. Webcast available. Learn about Nanobiotix and its disruptive therapeutic approaches

Webcast Nanotechnology NANOBIOTIX Therapeutic Approaches Jefferies London Healthcare Conference
BRIEF

published on 10/31/2025 at 08:05, 1 month 4 days ago

Nanobiotix Secures $71 Million Agreement with HealthCare Royalty

Long-term Growth HealthCare Royalty NANOBIOTIX Royalty Agreement Oncology Development
PRESS RELEASE

published on 10/31/2025 at 08:00, 1 month 4 days ago

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix announces $71M strategic royalty monetization agreement with Healthcare Royalty, extending cash runway and enabling long-term growth in cancer treatment

Cancer Treatment HealthCare Royalty Financial Agreement NANOBIOTIX Royalty Monetization
BRIEF

published on 10/01/2025 at 22:20, 2 months 3 days ago

NANOBIOTIX Reveals Promising Phase 1 Study Results for Esophageal Cancer Treatment

Phase 1 Study Radiotherapy Adverse Events JNJ-1900 (NBTXR3) Esophageal Cancer
PRESS RELEASE

published on 10/01/2025 at 22:15, 2 months 3 days ago

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Nanobiotix announces first data from Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with esophageal cancer. Results presented at ASTRO 2025 Annual Meeting

NANOBIOTIX Phase 1 Study JNJ-1900 Esophageal Cancer ASTRO
BRIEF

published on 09/30/2025 at 22:20, 2 months 4 days ago

Nanobiotix: Financial results and clinical progress in the first half of 2025

Financial Results Biotechnology NANOBIOTIX Johnson & Johnson JNJ-1900

1 2 ... 8

Accesswire

Published on 12/05/2025 at 02:35, 1 hour 59 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 4 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 3 hours 34 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 29 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 34 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 4 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 43 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 9 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 19 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 24 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 10 hours 34 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 49 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 50 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 33 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE